Zein Najjar
| Zein Najjar | |
|---|---|
| Executive at Altar Group | |
 Zein Najjar in 2048 | |
| Senior VP, Business Development | |
| In Office | 19 Apr 2048 - Present |
| CEO | TBD |
| Supervisor | COO |
| Preceded by | TBD |
| Succeeded by | TBD |
| Salary | $3,320,600 |
| Regional Director, Arabian Gulf | |
| In Office | 21 Dec 2044 - 18 Apr 2048 |
| CEO | TBD |
| Supervisor | VP |
| Preceded by | TBD |
| Succeeded by | TBD |
| Consort of the Chitral Household | |
| In Office | 14 Jan 2030 - 8 Jul 2040 |
| Patron | Muhammad Zubair Khan |
| Chief of Staff | TBD |
| Preceded by | TBD |
| Succeeded by | TBD |
| Personal Information | |
| Born | 29 October 2013 (age 37) Richmond, Virginia United States of America |
| Nationality | .png){kind=small} United States |
| Height | 165 cm (5'5") |
| Breasts | 32C |
| Hair | Black |
| Eyes | Hazel |
| Dress Size | 4 |
| Education | Harvard University (BA) Oxford University (MBA) |
| Spouse | Muhammad Zubair Khan (m. 2040) |
| Family | Ahmed Najjar (father) |
Jessica Kristin Stroud, PhD (born 6 June 1999) is an American entrepreneur, scientist and philanthropist who has been serving since 5 January 2030 as Chief Executive Officer of Nimbus Therapeutics Inc., the company she co-founded alongside TBD and TBD. Previously, she worked at Impossible Foods, Inc. from 2026 to 2030, rising to become the director of the company's global research center in April 2029. She has also been a trustee of the Kao Foundation since 16 February 2032, and is known for frequently championing environmental and social causes.
Throughout Stroud's career, she has maintained a strong interest in food science and genetics. While still a PhD candidate, she worked as a research associate with the Good Food Institute in Arlington, Virginia. In 2026, she completed her PhD thesis on alternative proteins and the environmental impact of their widespread adoption. For this, she was awarded the Newcomb Cleveland Prize in 2027.
Stroud co-founded Nimbus Therapeutics in January 2030 and has been the company's CEO since its inception. She initially provided the company with $1.5 million from her own personal funds as seed capital. In December that same year, Nimbus announced that it had developed a sublingual drug delivery system based on nanofibers obtained from plants, and that a patent application was pending. Under Stroud's leadership, Nimbus has since gone on to achieve an annual run-rate revenue of $49 million, and has raised two funding rounds from investors including Quest Ventures, Legend Capital and Nutriven. As of December 2034, Nimbus was valued at $320 million.